Evidence map›Paper›PMID 40739579›Full record

ArticleAlzheimer's research & therapy2025

Integrated plasma and red blood cell membrane lipidomics analysis unveils novel biomarker panel for Alzheimer's disease.

Dandan He, Yaran Bao, Siyi Yuan, Yingji Wang, Jingbo Cai, Fangfang Xu, Tiantian Chang, Pei Zhang, Menglu Yue, Xiaodong Pan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Brain Sphingolipid and Phospholipid Levels Are Altered in XK Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dandan He *Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, Jiangsu, China.
Yaran Bao *Department of Pharmaceutical Analysis, College of Pharmacy, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, Jiangsu, China.
Siyi YuanDepartment of Pharmaceutical Analysis, College of Pharmacy, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, Jiangsu, China.
Yingji WangDepartment of Pharmaceutical Analysis, College of Pharmacy, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, Jiangsu, China.
Jingbo CaiGeriatric Hospital of Nanjing Medical University, #65 Jiangsu Rd, Nanjing, 210009, Jiangsu, China.
Fangfang XuGeriatric Hospital of Nanjing Medical University, #65 Jiangsu Rd, Nanjing, 210009, Jiangsu, China.
Tiantian ChangGeriatric Hospital of Nanjing Medical University, #65 Jiangsu Rd, Nanjing, 210009, Jiangsu, China.
Pei ZhangGeriatric Hospital of Nanjing Medical University, #65 Jiangsu Rd, Nanjing, 210009, Jiangsu, China.
Menglu YueSchool of Science, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, Jiangsu, China.
Xiaodong PanGeriatric Hospital of Nanjing Medical University, #65 Jiangsu Rd, Nanjing, 210009, Jiangsu, China. panxd120@126.com.
Haiping HaoState Key Laboratory of Natural Medicines, Jiangsu Provincial Key Laboratory of Targetome and Innovative Drugs, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, Jiangsu, China. haipinghao@cpu.edu.cn.
Qiuling ZhengDepartment of Pharmaceutical Analysis, College of Pharmacy, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, Jiangsu, China. qiuling_zheng@cpu.edu.cn.

Funding

Major Science and Technology Project of Jiangsu Province BG2024045Overseas Expertise Introduction Project for Discipline Innovation G20582017001Sanming Project of Medicine in Shenzhen SZSM202301035the Major State Basic Research Development Program of China 2021YFA1301300the National Natural Science Foundation of China 81930109 and 82321005the Natural Science Foundation of Jiangsu Province BK20161587the Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University SKLNMZZ202402
6 · The paper itself

Abstract

backgroundDiscovering new biomarkers for Alzheimer's disease (AD) are significant for early diagnosis and monitoring disease's progression. Blood-based lipid biomarkers, particularly from red cell membranes, offer a non-invasive alternative, providing insights into AD progression and potential therapeutic targets.

methodsThis study innovatively incorporates red cell membrane (RCM) lipids, which reflect chronic physiological alterations and are linked to AD pathogenesis. A comprehensive lipid detection platform was employed to analyze lipid profiles from 156 individuals, including normal subjects, those with amnestic mild cognitive impairment, and AD patients. Differential lipids were identified and validated to be AD-associated by correlation analysis and big data analysis. Multi-dimensional criteria were applied to select potential lipid biomarkers.

resultsPLS-DA revealed distinct lipidomic profiles between groups, with RCM samples showing superior separation. 138 differentially expressed lipids were identified and enriched in AD-related pathways, many uniquely associated with the RCM. Six lipids were selected as a potential biomarker panel for AD based on multi-dimensional criteria.

conclusionsRCM shows broader lipidomic relevance and stronger biomarker potential compared to plasma. Integrating RCM lipids with plasma analysis enhances AD diagnostics and highlights the potential of RCM as an underexplored biomarker resource.

Indexed as

Alzheimer DiseaseErythrocyte MembraneLipidomicsAgedAged, 80 and overBiomarkersCognitive DysfunctionFemaleHumansLipidsMaleMiddle AgedBiomarkersLipidsAlzheimer’s diseaseBiomarker discoveryLipidomicsUPLC-MS

Identifiers

PMID40739579
PMCPMC12309142

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.